Terns Pharmaceuticals, Inc.
TERN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.42 | 0.21 | 0.39 | -0.15 |
| FCF Yield | -15.91% | -14.58% | -13.46% | -23.60% |
| EV / EBITDA | -3.20 | -3.75 | -3.81 | -2.65 |
| Quality | ||||
| ROIC | -29.30% | -39.98% | -22.29% | -31.24% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 48.80% |
| Cash Conversion Ratio | 0.79 | 0.75 | 0.81 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | – | – |
| Free Cash Flow Growth | -3.88% | -36.57% | -17.12% | -38.74% |
| Safety | ||||
| Net Debt / EBITDA | 1.83 | 0.78 | 2.41 | 0.97 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,041.97 | -581.81 | -1,515.61 |